Table 1 Patient characteristics

Patients, n (%)

625 (100)

387 (100)

238 (100)

139 (100)

61 (100)

38 (100)

Male (%)

394 (63.0)

235 (60.7)

159 (66.8)

89 (64.0)

42 (68.9)

28 (73.7)

Age, median (25th -75th percentile)

66.0 (54.5–75.0)

61.0 (48.0–71.0)

71.5 (64.0–79.0)

73.0 (62.0–80.0)

70.0 (63.5–76.0)

73.0 (67.8–77.3)

BMI, median (25th -75th percentile)

25.7 (22.4–29.5)

25.3 (22.1–29.4)

26.0 (22.9–29.6)

25.5 (22.4–29.7)

26.7 (24.3–30.2)

25.7 (22.9–28.0)

Employment, n (%)

56 (9.0)

42 (10.9)

14 (5.9)

6 (4.3)

1 (1.6)

7 (18.4)

Time-in-therapeutic INR range, median % (25th -75th percentile)

n.a.

n.a.

n.a.

n.a.

57.2 (39.5–72.3)

n.a.

Aetiology of ESKD, n (%)

-

-

-

-

-

-

Diabetic NP

160 (25.6)

97 (25.1)

63 (26.5)

35 (25.2)

20 (32.8)

8 (21.1)

Vascular NP

121 (19.4)

71 (18.3)

50 (21.0)

31 (22.3)

12 (19.7)

7 (18.4)

Glomerulonephritis

81 (13.0)

59 (15.2)

22 (9.2)

11 (7.9)

6 (9.8)

5 (13.2)

Atrophic NP

57 (9.1)

36 (9.3)

21 (8.8)

13 (9.4)

4 (6.6)

4 (10.5)

Cystic nonhereditary NP

36 (5.8)

19 (4.9)

17 (7.1)

11 (7.9)

3 (4.9)

3 (7.9)

Hereditary NP

31 (5.0)

21 (5.4)

10 (4.2)

7 (5.0)

1 (1.6)

2 (5.3)

Nephrectomy

20 (3.2)

9 (2.3)

11 (4.6)

4 (2.9)

6 (9.8)

1 (2.6)

Toxic NP

28 (4.5)

12 (3.1)

16 (6.7)

9 (6.5)

3 (4.9)

4 (10.5)

Other causes

91 (14.6)

63 (16.3)

28 (11.8)

18 (12.9)

6 (9.8)

4 (10.5)

Dialysis history, n (%)

-

-

-

-

-

-

History of kidney transplantation

90 (14.4)

57 (14.7)

33 (13.9)

16 (11.5)

8 (13.1)

9 (23.7)

History of peritoneal dialysis

46 (7.4)

29 (7.5)

17 (7.1)

9 (6.5)

5 (8.2)

3 (7.9)

Dialysis parameters, median (25th -75th percentile)

-

-

-

-

-

-

Remaining diuresis, ml/day

500 (0-1000)

500 (0-1000)

500 (0-1000)

500 (0-1000)

400 (0-1000)

200 (0-1000)

Time on haemodialysis, years

2.7 (1.0–5.0)

2.5 (1.0–5.0)

3.0 (1.0–6.0)

3.0 (1.0–6.0)

3.0 (1.7-7.0)

2.3 (1.0–5.0)

Comorbidities, n (%)

-

-

-

-

-

-

History of stroke or TIA

127 (20.3)

64 (16.5)

63 (26.5)

25 (18.0)

24 (39.3)

14 (36.8)

History of myocardial infarction

104 (16.6)

53 (13.7)

51 (21.4)

31 (22.3)

12 (19.7)

8 (21.1)

Coronary artery disease

232 (37.1)

121 (31.3)

111 (46.6)

62 (44.6)

29 (47.5)

20 (52.6)

Artificial heart valve

43 (6.9)

21 (5.4)

22 (9.2)

10 (7.2)

8 (13.1)

4 (10.5)

History of VTE

61 (9.8)

28 (7.2)

33 (13.9)

16 (11.5)

13 (21.3)

4 (10.5)

Deep vein thrombosis

43 (6.9)

19 (4.9)

24 (10.1)

10 (7.2)

10 (16.4)

4 (10.5)

Pulmonary embolism

32 (5.1)

16 (4.1)

16 (6.7)

7 (5.0)

8 (13.1)

1 (2.6)

Peripheral artery disease

197 (31.5)

111 (28.7)

86 (36.1)

48 (34.5)

20 (32.8)

18 (47.4)

Diabetes

237 (37.9)

135 (34.9)

102 (42.9)

63 (45.3)

28 (45.9)

11 (28.9)

Hypertension

574 (91.8)

355 (91.7)

219 (92.0)

128 (92.1)

57 (93.4)

34 (89.5)

Congestive heart failure

183 (29.3)

91 (23.5)

92 (38.7)

49 (35.3)

27 (44.3)

16 (42.1)

Cancer history or active

152 (24.3)

76 (19.6)

76 (31.9)

44 (31.7)

19 (31.1)

13 (34.2)

Current and past smokers

305 (48.8)

191 (49.4)

114 (47.9)

64 (46.0)

37 (60.7)

13 (34.2)

History of major bleeding

67 (10.7)

38 (9.8)

29 (12.2)

20 (14.4)

5 (8.2)

4 (10.5)

History of intracranial bleeding

18 (2.9)

8 (2.1)

10 (4.2)

7 (5.0)

2 (3.3)

1 (2.6)

CHA2DS2-VASc score, median (25th -75th percentile)

4 (2–5)

4 (3–5)

4 (3–5)

4 (3–5)

4 (3–5)

4 (3–5)

HAS-BLED score, median (25th -75th percentile)

3 (2–4)

4 (3–4)

4 (3–4)

4 (3–4)

3 (2–4)

4 (3–5)

Antiplatelet medication

345 (55.2)

208 (53.7)

137 (57.6)

98 (70.5)

18 (29.5)

21 (55.3)